AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol and betamethasone 17-valerate (1 mg/g) creams
Number of subjects: 40
Study 8949429 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol monotherapy (once daily)
Number of subjects: 40
Study 2294687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (walking and jogging at >= 70% maximal heart rate reserve for 1 hour 3 times/week for 12 weeks)
Number of subjects: 37
Study 2294687 — intervention group
Group type: COMPARATOR
Intervention: Strength and flexibility training (1 hour of circuit Nautilus training 2 times/week for 12 weeks)
Number of subjects: 37
Study 2294687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 37
Study 709569 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (ETG)
Number of subjects: 0
Study 709569 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (NTG)
Number of subjects: 0
Study 31401654 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO SNP rs9939609 as an instrumental variable in MR models
Number of subjects: 3654
Study 31401654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of protein intake
Number of subjects: 3654
Study 28702809 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic formoterol (2 × 27 µg)
Number of subjects: 19
Study 28702809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25282578 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 360
Study 25282578 — intervention group
Group type: COMPARATOR
Intervention: In-person brief intervention (IBI)
Number of subjects: 360
Study 24963111 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3.5 g daily for 4 weeks)
Number of subjects: 41
Study 24963111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure measurement
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure measurement
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density lipoprotein measurement
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment factors
Number of subjects: 326
Study 22704274 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' treatment effect
Number of subjects: 326
Study 19089782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days
Number of subjects: 796
Study 19089782 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg daily for 5 days
Number of subjects: 796
Study 19089782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 5 days
Number of subjects: 796
Study 19089782 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous pregnancies (control group)
Number of subjects: 796
Study 17879495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with oral prednisolone (1 mg/kg body weight for 7 days, tapering off over 3 days)
Number of subjects: 100
Study 17879495 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic monotherapy
Number of subjects: 100
Study 15080019 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg IV and 16 mg in PCA pump)
Number of subjects: 374
Study 15080019 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 374
Study 12479110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120
Study 12479110 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120
Study 12479110 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tramadol (6 mg/kg), morphine (0.12 mg/kg), and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120
Study 9667255 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week regimen
Number of subjects: 646
Study 9667255 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 646
Study 8120960 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 179
Study 8120960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179
Study 8120960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 3674580 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 800 micrograms per day
Number of subjects: 26
Study 3674580 — intervention group
Group type: COMPARATOR
Intervention: Oral theophylline
Number of subjects: 26
Study 3674580 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) changed to oral theophylline
Number of subjects: 26
Study 31844906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia tool in addition to the booklet
Number of subjects: 225
Study 31844906 — intervention group
Group type: COMPARATOR
Intervention: Printed booklet alone
Number of subjects: 225
Study 31844906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia tool
Number of subjects: 225
Study 29247273 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training hypoxic group (H-HRV)
Number of subjects: 24
Study 29247273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (H)
Number of subjects: 24
Study 29247273 — intervention group
Group type: COMPARATOR
Intervention: Normoxia group (N)
Number of subjects: 24
Study 26639857 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention (home visits by community-based surveillance volunteers)
Number of subjects: 7848
Study 26639857 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention
Number of subjects: 7848
Study 24955452 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly endoscopic variceal ligation (EVL)
Number of subjects: 70
Study 24955452 — intervention group
Group type: COMPARATOR
Intervention: Biweekly endoscopic variceal ligation (EVL)
Number of subjects: 70
Study 23341517 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with concurrent cisplatin 100 mg/m(2) on days 1, 22, and 43 of RT (arm A)
Number of subjects: 153
Study 23341517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioradiotherapy (BRT) with concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B)
Number of subjects: 153
Study 20626512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneling excision technique
Number of subjects: 40
Study 20626512 — intervention group
Group type: COMPARATOR
Intervention: Conventional open method
Number of subjects: 40
Study 19020701 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Research Council scale
Number of subjects: 31
Study 19020701 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council scale
Number of subjects: 31
Study 19020701 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal relative force measurements
Number of subjects: 31
Study 18822428 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose 0.75 microg/kg/min for 3 hours then maintenance 0.2 microg/kg/min until 18 hours after birth)
Number of subjects: 90
Study 18822428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18822428 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 90
Study 15888053 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 23
Study 15888053 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 23
Study 11893047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (LB)
Number of subjects: 3
Study 11893047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB)
Number of subjects: 3
Study 8995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular dysfunction (ejection fraction < or = 28 percent)
Number of subjects: 2231
Study 8995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2231
Study 8995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ejection fraction
Number of subjects: 2231
Study 8995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of aspirin or anticoagulant therapy
Number of subjects: 2231
Study 8995087 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic agents and captopril
Number of subjects: 2231
Study 8995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 2231
Study 9371324 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 2
Study 9371324 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid growth factors
Number of subjects: 2
Study 2959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 386
Study 2959716 — intervention group
Group type: COMPARATOR
Intervention: Elective coronary angioplasty (7 day)
Number of subjects: 386
Study 2959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA)
Number of subjects: 386
Study 2959716 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency coronary bypass surgery
Number of subjects: 386
Study 30763405 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment before immunisation
Number of subjects: 254
Study 30763405 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment at immunisation
Number of subjects: 254
Study 30763405 — intervention group
Group type: COMPARATOR
Intervention: S. mansoni-infected children
Number of subjects: 254
Study 29547049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (de novo group)
Number of subjects: 115
Study 29547049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (prior octreotide group)
Number of subjects: 115
Study 29547049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (de novo group)
Number of subjects: 115
Study 29547049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (prior octreotide group)
Number of subjects: 115
Study 26909683 — intervention group
Group type: EXPERIMENTAL
Intervention: HNC (Helping the Noncompliant Child)
Number of subjects: 130
Study 26909683 — intervention group
Group type: EXPERIMENTAL
Intervention: NFPP (New Forest Parenting Programme)
Number of subjects: 130
Study 24338935 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (titrating dose, 12.5-50 mg once daily)
Number of subjects: 2000
Study 24338935 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (titrating dose, 0.1-0.3 mg twice daily)
Number of subjects: 2000
Study 23198694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese diabetes group visit program (12 monthly group visit sessions)
Number of subjects: 208
Study 23198694 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study 19081412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents (SESs)
Number of subjects: 200
Study 19081412 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal BxVelocity stents (BMSs)
Number of subjects: 200
Study 17403121 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone + metformin (8/2000 mg)
Number of subjects: 324
Study 17403121 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 324
Study 15505875 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioisotope occult lesion localization (ROLL)
Number of subjects: 95
Study 15505875 — intervention group
Group type: COMPARATOR
Intervention: Wire localization
Number of subjects: 95
Study 11136485 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate, 50 mg once daily
Number of subjects: 46
Study 11136485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9693995 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep measures in OAD patients
Number of subjects: 116
Study 9693995 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep measures in DAT patients
Number of subjects: 116
Study 9693995 — intervention group
Group type: COMPARATOR
Intervention: REM sleep measures in healthy controls
Number of subjects: 116
Study 7935635 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodinated vasoactive intestinal peptide (VIP) administered as a single intravenous bolus injection (300 pmol [1 microgram])
Number of subjects: 79
Study 7935635 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin analogues
Number of subjects: 79
Study 3588972 — intervention group
Group type: EXPERIMENTAL
Intervention: DHV‐PGE2 ME, 120 micrograms
Number of subjects: 12
Study 3588972 — intervention group
Group type: EXPERIMENTAL
Intervention: DHV‐PGE2 ME, 30 micrograms
Number of subjects: 12
Study 3588972 — intervention group
Group type: COMPARATOR
Intervention: Inactive vehicle
Number of subjects: 12
Study 29156056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 8000 IU/day
Number of subjects: 95
Study 29156056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 27475753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75-450 mg/day)
Number of subjects: 107
Study 27475753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 23617693 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 5 mg/day for 16 weeks
Number of subjects: 0
Study 23617693 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin 5 mg/day after 16 weeks of placebo
Number of subjects: 0
Study 23617693 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 5 mg/day for 32 weeks
Number of subjects: 0
Study 20220604 — intervention group
Group type: EXPERIMENTAL
Intervention: TIP intervention (psychosocial intervention targeting psychological barriers to depression care)
Number of subjects: 0
Study 20220604 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 17655947 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin (low dose)
Number of subjects: 60
Study 17655947 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (high dose)
Number of subjects: 60
Study 17655947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17063827 — intervention group
Group type: COMPARATOR
Intervention: Microwave energy in the frequency range of 250 approximately 550MHz irradiated on an acupuncture point.
Number of subjects: 150
Study 12462550 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy (HRT)
Number of subjects: 17835
Study 12462550 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 17835
Study 12462550 — intervention group
Group type: COMPARATOR
Intervention: Never use of PMH
Number of subjects: 17835
Study 11396038 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based dental health education program for 6 months
Number of subjects: 2678
Study 11396038 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based dental health education program for 12 months
Number of subjects: 2678
Study 11396038 — intervention group
Group type: COMPARATOR
Intervention: Early intervention group (6 months)
Number of subjects: 2678
Study 11396038 — intervention group
Group type: COMPARATOR
Intervention: Early intervention group (12 months)
Number of subjects: 2678
Study 7740333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV vinorelbine
Number of subjects: 0
Study 7740333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV vinorelbine (first-line therapy)
Number of subjects: 0
Study 2201742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg every 12 h for 5 days
Number of subjects: 121
Study 2201742 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, 500 mg every 6 h for 5 days
Number of subjects: 121
Study 2201742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 121
Study 2201742 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 121
Study 7026260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isoxsuprine 20 mg
Number of subjects: 7
Study 7026260 — intervention group
Group type: COMPARATOR
Intervention: Oral isoxsuprine 20 mg
Number of subjects: 7
Study 7026260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31092668 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided web‐based transdiagnostic individually tailored intervention (7 online sessions over 4 to 7 weeks, with a booster session 4 weeks after completion)
Number of subjects: 0
Study 28526720 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.2 mg/m2
Number of subjects: 66
Study 26484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS during RT
Number of subjects: 22
Study 26484510 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS during RT
Number of subjects: 22
Study 23722126 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel applied twice a day for one week
Number of subjects: 88
Study 23722126 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel applied twice a day for one week
Number of subjects: 88
Study 21321426 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of Panax ginseng (PG)
Number of subjects: 9
Study 21321426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19761681 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day)
Number of subjects: 44
Study 19761681 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day)
Number of subjects: 44
Study 19761681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (added if target blood pressure not achieved)
Number of subjects: 44
Study 19761681 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ACEi and ARB combined)
Number of subjects: 44
Study 17762803 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy
Number of subjects: 120
Study 17762803 — intervention group
Group type: COMPARATOR
Intervention: Sham neck massage
Number of subjects: 120
Study 17762803 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 120
Study 15177823 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral forced nostril breathing (UFNB) through the left nostril
Number of subjects: 0
Study 15177823 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral forced nostril breathing (UFNB) through the right nostril
Number of subjects: 0
Study 15177823 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent UFNB (breathing through dominant nostril)
Number of subjects: 0
Study 15177823 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent UFNB (breathing through non-dominant nostril)
Number of subjects: 0
Study 15177823 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 11273588 — intervention group
Group type: EXPERIMENTAL
Intervention: LVSFU2 (bimonthly regimen)
Number of subjects: 905
Study 11273588 — intervention group
Group type: COMPARATOR
Intervention: FUFOL (monthly regimen)
Number of subjects: 905
Study 11273588 — intervention group
Group type: EXPERIMENTAL
Intervention: LVSFU2
Number of subjects: 905
Study 10896408 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (1500 mg)
Number of subjects: 20
Study 10896408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (1500 mg)
Number of subjects: 20
Study 10896408 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine
Number of subjects: 20
Study 10896408 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 20
Study 8551452 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity viscoelastic used for intraocular lens (IOL) implantation
Number of subjects: 2
Study 8551452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity viscoelastic used for intraocular lens (IOL) implantation
Number of subjects: 2
Study 8551452 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 2
Study 2229459 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 107
Study 2229459 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 107
Study 2229459 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 107
Study 2229459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 354330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release amitriptyline (Saroten Retard)
Number of subjects: 24
Study 354330 — intervention group
Group type: COMPARATOR
Intervention: Conventional amitriptyline tablets (Saroten)
Number of subjects: 24
Study 29023998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including behavioral lifestyle modification program and pranayama sessions
Number of subjects: 0
Study 29023998 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study 26840887 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate with a higher content of bioactive collagen peptides (H-CP)
Number of subjects: 0
Study 26840887 — intervention group
Group type: COMPARATOR
Intervention: Collagen hydrolysate with a lower content of bioactive collagen peptides (L-CP)
Number of subjects: 0
Study 26840887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24770406 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-skin thinning technique (test group)
Number of subjects: 36
Study 24770406 — intervention group
Group type: COMPARATOR
Intervention: Flap technique (control group)
Number of subjects: 36
Study 24770406 — intervention group
Group type: COMPARATOR
Intervention: Dermatome technique (control group)
Number of subjects: 36